Venetoclax Registry (VENreg)

Hannover Medical School (MHH)

Status: Enrolling

Conditions: Acute Myeloid Leukemia

Treatments: Drug: Venetoclax

Study type: Observational

Funder types: Other

Identifiers

NCT03662724

7972_BO_K_2018

Details and patient eligibility

About

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax

Full description

The aim of this study is to document all patients with AML who are treated with the BCL2 inhibitor Venetoclax outside a clinical trial in all hospitals participating in this registry study in a standardised manner. Data is collected retrospectively and multi-centric. It is neither a therapy study nor is the therapy influenced by this study.

1. Systematic and uniform collection and documentation of all patients treated with the BCL2 inhibitor Venetoclax.
2. Collection and integrative analysis of clinical data of included patients.
3. Mutation analysis of available patient samples and correlation with clinical parameters.

Enrollment: 100 estimated patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

relapsed/refractory AML

Exclusion criteria